Nortran Pharmaceutical -NRT.V Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: F. Jay Abella, III who wrote (750)	5/17/1998 9:48:00 PM
From: Mr. Forthright	Read Replies (1) of 1185

Thanks for taking the time to answer my questions. Hopefully you understand my problems with this thread: 1) People falsely assuming that because Hoffman is involved success is assured. 2) People underestimating the time and risks of the regulatory process. 3) Apparent leaks of insider information. 4) Over-promotion of an early stage company. <<Keep in mind, the NPV of 10% of NRT's technology was $86.5mm US. Not bad.>> Could you please expand on this statement. I am not sure I follow you on this one. Also what do you evaluate the yearly market potential of the drugs being developed to be? Analysis of potential drug price, number of cases and market penetration would be useful. What do think the discount factor on these potential cash flows should be? Do you have more info on the Hoffman deal than the basic info released by the company? It would help us evaluate the potential of the deal. Right?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next